Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure
- 1 December 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 338 (4) , 1865-1874
- https://doi.org/10.1016/j.bbrc.2005.10.106
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Hydralazine decreases sodium nitroprusside-induced rat aortic ring relaxation and increased cGMP production by rat aortic myocytesLife Sciences, 2005
- Heterozygous Deficiency of Manganese Superoxide Dismutase in Mice (Mn-SOD+/-): A Novel Approach to Assess the Role of Oxidative Stress for the Development of Nitrate ToleranceMolecular Pharmacology, 2005
- Novel Mechanism of Action for HydralazineCirculation Research, 2004
- Oxidation and Nitrosation in the Nitrogen Monoxide/Superoxide SystemJournal of Biological Chemistry, 2002
- Mitochondria, oxygen free radicals, and apoptosisAmerican Journal of Medical Genetics, 2001
- N-α-Tosyl-l-Lysine Chloromethylketone Prevents Expression of iNOS in Vascular Smooth Muscle by Blocking Activation of NF-κBArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.Journal of Clinical Investigation, 1996
- Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failureJournal of the American College of Cardiology, 1995
- Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.Journal of Clinical Investigation, 1995
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986